Zydus Lifesciences has signed an agreement with Myriad Genetics to introduce MyRisk Hereditary Cancer Test, MyChoice HRD Plus, the Homologous Recombination Deficiency (HRD) test and the Prolaris Prostate Cancer Prognostic Test to patients, clinicians and healthcare systems across India. With the increasing incidence of cancers globally, the MyRisk Test can help people safeguard their health and take precautionary steps and lifestyle changes that can minimise the risk of cancer. In patients suffering from prostate and ovarian cancers, the Prolaris Test and MyChoice HRD Plus Test, respectively, can help patients understand the disease progression and inform the right treatment path.

Commenting on this, Dr Sharvil P Patel, Managing Director, Zydus, said, “This agreement marks a major step in expanding access to precision diagnostic tests for cancer treatment in India. The prostate and ovarian cancer tests help doctors with actionable insights to develop personalised treatment plans, predict disease progression, arrive at treatment decisions and streamline clinical workflows. We are also bringing a test which will help identify hereditary risks in patients and their families. Enabling access to these critical diagnostic tests will benefit patients in getting better clinical outcomes and support their fight against cancer.

“Reaffirming Zydus’ deep commitment to patient centricity and precision oncology, this collaboration with Myriad Genetics will strengthen clinician education and diagnostic infrastructure so that patients benefit from earlier, more accurate risk assessment and more confident treatment planning. Together, we aspire to make personalised, evidence-based cancer care accessible to every patient who needs it, helping them navigate their journey with greater clarity and support,” he added.

As part of this agreement, Zydus will exclusively market, create awareness, access and engage clinicians on three of Myriad Genetics’ broadly validated diagnostic platforms, MyRisk Hereditary Cancer Test, MyChoice HRD Plus Test for ovarian cancer, and Prolaris^, a gene expression Prostate Cancer Prognostic Test.

“This collaboration with Zydus is an important step forward in expanding precision oncology across India. Myriad tests aim to empower clinicians with actionable information to assess risk, understand tumour biology and guide truly personalised care with greater clarity, confidence and hope as they navigate critical health decisions,” said Brian Donnelly, Chief Commercial Officer, Myriad Genetics.

These tests have been widely adopted in the North America, Europe and major global cancer centres, and will now empower Indian oncologists with cutting-edge genomic decision-support tools.

The MyRisk Test is a germline multigene panel for individuals with personal or family history suggestive of hereditary cancer. It detects pathogenic variants in high, moderate and emerging-risk genes to estimate lifetime cancer risk and inform personalised prevention strategies.

The MyRisk Test is a comprehensive panel which analyses 63 clinically significant genes (BRCA1, BRCA2, PALB2, ATM, TP53, MLH1, MSH2, etc.) covering cancer types like breast, ovarian, lung, pancreatic, colorectal, endometrial, prostate, gastric and melanoma. It also includes RiskScore which combines genetic and clinical data to predict five-year and lifetime breast cancer risk, enabling individualised screening and prevention plans.